Publication | Open Access
136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
232
Citations
0
References
2016
Year
Tumor BiologyMedicinePathologyCancer Cell BiologyMolecular OncologyCancer TreatmentCancer GeneticsOncologyCell BiologyLung CancerCancer Research
No additional data available for this publication yet. Check back later!